18085-97-7
18085-97-7 結(jié)構(gòu)式
基本信息
爵篩奧素
棕矢車菊素
JACOSIDIN
棕矢車菊素對照品,
棕矢車菊素、合金歡素
棕矢車菊素(標準品)
棕矢車菊素(合金歡素,爵篩奧素)
4',5,7-三羥基-3',6-二甲氧基黃酮
4',5,7-三羥基-3',6-二甲氧基苯并吡喃-4-酮
Jaseosidin
JACEOSIDIN
Jacesiolin
6-Hydroxyluteolin 3',6-dimethyl ether
4',5,7-Trihydroxy-3',6-dimethoxyflavone
3',6-Dimethoxy-4',5,7-trihydroxyflavone
5,7-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)-6-methoxy-chromen-4-one
5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxy-4H-chromen-4-one
5,7-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-6-methoxy-4H-1-benzopyran-4-one
物理化學性質(zhì)
常見問題列表
從艾葉中分離得到的棕矢車菊素和異澤蘭黃素屬于環(huán)烯醚萜苷類，其主要具有清熱、鎮(zhèn)痛等相關(guān)活性作用。
|
Bax
|
COX-2
|
Jaceosidin (30, 50, 75 μM) induces apoptosis in human renal carcinoma Caki cells after treatment for 24 h, shows no obvious effect on normal cells.
Jaceosidin (75 μM) reduces MMP levels and causes cytochrome c release into the cytoplasm through Bax activation.
Jaceosidin-mediated apoptosis is involved in downregulation of Mcl-1, c-FLIP expression, which is via inhibition of NF-κB and/or Sp1 transcriptional activity.
Jaceosidin shows cytostatic activity to HES and HESC cells with IC
50
s of 52.68 and 55.10 μM, and is less cytotocxic on Hec1 A and KLE (IC
50
, 70.54, 147.14 μM, respectively), after treatment for 48 h.
Cell Viability Assay
| Cell Line: | Hec1A, KLE, HES and HESC cells |
| Concentration: | 3.125, 6.25, 12.5, 25, 50, and 100 μM |
| Incubation Time: | 48 hour |
| Result: | Showed cytostatic activity to HES and HESC cells with IC 50 s of 52.68 and 55.10 μM, less cytotocxic on Hec1 A and KLE (IC 50 , 70.54, 147.14 μM). |
Jaceosidin (10 and 20 mg/kg, p.o., once a day for 3 days) blocks carrageenan-induced increase in leukocyte number and protein levels in air pouch exudates in mice.
Jaceosidin (10, 20 mg/kg, p.o.) suppresses COX-2 expression and NF-κB activation in mice.
Jaceosidin (20 mg/kg, p.o. for 2 hours) reduces hind paw edema volume in rats.
| Animal Model: | 5-week-old male BALB/c mice (23-26 g) |
| Dosage: | 10 and 20 mg/kg |
| Administration: | P.O. once a day for 3 days |
| Result: | Decreased the volumes of exudates (inflammatory markers), cell number and protein levels. Inhibited TNF-α by 46.7% and 50.8%, IL-1β by 46.0% and 44.7%, and PGE2 by 21.7% and 16.9%, respectively, at 20 mg/kg. Blocked COX-2 expression and NF-κB activation. |
| Animal Model: | Male Sprague-Dawley rats (180-200 g) |
| Dosage: | 20 mg/kg |
| Administration: | P.O., for 2 hour |
| Result: | Reduced hind paw edema volume by 27.1% at 1 h, and 24.0% at 2 h, respectively. |